MAPT and Alzheimer disease: The CSF findings of reduced Aβ40 and Aβ42 in both patients align with the expected biomarker profile for CAA and its variants.4Furthermore, the elevated p-tau in one case suggests that concomitant AD pathology may be present, a factor that could influence prognosis or long-term management.